证券代码：301539 证券简称：宏鑫科技 公告编号：2026-005 二、募集资金存放和管理情况 为了规范募集资金的管理和使用，保护投资者权益，本公司依照《上市公司 募集资金监管规则》和《深圳证券交易所上市公司自律监管指引第2号——创业 板上市公司规范运作》等文件的规定，结合本公司实际情况，制定了《浙江宏鑫 科技股份有限公司募集资金管理制度》（以下简称"管理制度"）。根据管理制 度并结合经营需要，本公司对募集资金实行专户存储，在银行设立募集资金使用 专户，并与开户银行、保荐机构签订了《募集资金专用账户管理协议》，对募集 资金的使用实施严格审批，以保证专款专用。 1 三、募集资金专户的情况 截至披露日，公司有 2 个募集资金专户，情况如下： | 序号 | 开户银行 | 银行账号 | 备注 | | --- | --- | --- | --- | | 1 | 上海浦东发展银行股份有限公司台州黄岩支行 | 81020078801888668888 | 本次注销 | | 2 | 中国工商银行股份有限公司台州黄岩支行 | 1207031129202466606 | 存续 | 浙江宏鑫科技股份有限公司 关于注销部分募集资 ...

格隆汇2月2日丨宏鑫科技(301539.SZ)在投资者互动平台表示，公司暂未涉及月球探测器、月球飞行器 相关零部件供应。公司锻造工艺生产的零部件具备高强度、轻量化、高可塑性的核心优势，前期与国内 某航天科技有限公司合作定点开发定子主壳体、折叠桨外转子壳体等核心零部件及车轮产品，该业务占 公司整体业务比重较小，不会对公司整体业绩产生重大的影响。 ...

证券日报网讯1月30日，宏鑫科技（301539）在互动平台回答投资者提问时表示，公司目前与国内某航 天科技（000901）有限公司的定点开发及采购合作，聚焦于低空经济领域飞行器的定子主壳体、折叠桨 外转子壳体等核心零部件及车轮产品，暂未涉及月球探测器、月球飞行器相关零部件供应。公司锻造工 艺生产的零部件具备高强度、轻量化、高可塑性的核心优势，后续公司将结合市场需求与自身技术优 势，积极探索相关领域的业务拓展可能性，后续相关进展将按规则披露。 ...

格隆汇1月30日丨宏鑫科技(301539.SZ)在投资者互动平台表示，低空经济迎来政策、技术、市场三重壁 垒突破的发展机遇，公司依托精密锻造、轻量化技术积累，目前公司已与低空经济头部企业达成合作并 签订定点采购协议，部分产品已进入样品测试评估阶段。同时公司持续加大研发投入，持续拓展业务范 围。后续公司将紧跟产业动态，深化技术创新与市场合作，充分发挥制造优势。 ...

证券代码：301539 证券简称：宏鑫科技 公告编号：2026-004 浙江宏鑫科技股份有限公司 关于变更签字注册会计师的公告 律组织的自律监管措施、纪律处分的情况，不存在违反《中国注册会计师职业道 德守则》对独立性要求的情形。 浙江宏鑫科技股份有限公司（以下简称"公司"）分别于 2025 年 4 月 16 日、 2025 年 5 月 8 日召开第二届董事会第十次会议、2024 年年度股东大会,审议通过 了《关于续聘 2025 年度审计机构的议案》，同意公司续聘天健会计师事务所（特 殊普通合伙）为公司 2025 年度审计机构。具体内容详见公司于 2025 年 4 月 18 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于续聘 2025 年度审计机构的 公告》（公告编号：2025-014）。 近日，公司收到天健会计师事务所（特殊普通合伙）出具的《关于变更签字 注册会计师的函》，现将相关事项公告如下： 一、签字注册会计师变更的情况 天健会计师事务所（特殊普通合伙）作为公司 2025 年度财务审计机构及内 部控制审计机构，原委派胡燕华和李亚娟作为签字注册会计师为公司提供审计服 务。由于天健会计师事务 ...

格隆汇1月30日丨宏鑫科技(301539.SZ)在投资者互动平台表示，低空经济迎来政策、技术、市场三重壁 垒突破的发展机遇，公司依托精密锻造、轻量化技术积累，目前公司已与低空经济头部企业达成合作并 签订定点采购协议，部分产品已进入样品测试评估阶段。同时公司持续加大研发投入，持续拓展业务范 围。后续公司将紧跟产业动态，深化技术创新与市场合作，充分发挥制造优势。 ...

Group 1 - The company, Hongxin Technology (301539), focuses on the research, design, manufacturing, and sales of forged aluminum alloy wheels for automobiles [1] - The main products of the company include forged aluminum alloy wheels for commercial vehicles and passenger vehicles [1]

Shareholder Reduction - New China Group's shareholder, New Work Group, plans to reduce its stake by no more than 3% [1] - Shuyuan Pingmin's shareholder, Alibaba Health, intends to reduce its stake by no more than 2% [1] - Zhejiang Yongqiang's shareholder, Xie Jianqiang, plans to reduce his stake by no more than 1.13% [1] - Xiangyu Medical's shareholder, Anyang Qixu, intends to reduce his stake by no more than 3% [1] - Zhangyue Technology's shareholder, Quantum Leap, plans to reduce its stake by no more than 1% [1] - Fudan Zhangjiang's shareholder, Yang Zongmeng, has reduced 10.3657 million shares [1] - Saiwei Times' shareholder, Zhongteng Investment, has reduced 12.1037 million shares [1] - Aokang International's shareholder, Xiang Jinyu, has cumulatively reduced 1.21% of the company's shares [1] - Fute Technology's shareholder, Changjiang Weilai Industrial Fund, has cumulatively reduced 1.6492% of the shares [1] - New Giant's shareholder, Suzhou Houqi, has cumulatively reduced 1.4997% of the shares [1] - Baolingbao's shareholder, De Pufutong, has cumulatively reduced 1.10689% of the shares [1] - Hongqiang's actual controller, Liu Lianjun, plans to reduce his stake by no more than 1% [1] - Yashiguangdian's shareholder, Bian Ruiqun, has cumulatively reduced 1.0695% of the shares [1] Other Financial Issues - Ruimao Tong has reported overdue debts amounting to approximately 856 million yuan [1] - *ST Dongjing is under investigation by the Securities Regulatory Commission due to independent director Fu Baoshan's suspected insider trading [1]

Group 1 - The company held its 14th meeting of the second board of directors on January 8, 2026, with all 7 directors present, and the meeting was conducted in accordance with the Company Law and the Articles of Association [2][4] - The board approved the proposal for investing in a new wheel production project, with a planned investment of approximately $50 million, including land purchase costs [3][13][14] - The board also approved the appointment of Hu Haiyan as the new Vice General Manager and Board Secretary, following the resignation of Wang Lei due to personal work adjustments [5][9][10] Group 2 - The new wheel production project will be implemented by the company's wholly-owned subsidiary, Tai Rui Industrial (Thailand) Co., Ltd., and will utilize self-owned and self-raised funds [13][14] - The project aims to enhance the company's production capacity to meet the overseas passenger vehicle wheel demand, leveraging Thailand's location advantages and policy support [14] - The investment does not involve related party transactions and does not constitute a major asset restructuring as defined by the China Securities Regulatory Commission [13]

Group 1 - Jinli Permanent Magnet expects a net profit of 660 million to 760 million yuan for 2025, representing a year-on-year growth of 127% to 161% [1] - Wens Foodstuffs anticipates a net profit of 5 billion to 5.5 billion yuan for 2025, a decrease of 40.73% to 46.12% compared to the previous year [2] - New Open Source plans to repurchase shares worth 40 million to 50 million yuan, with a maximum repurchase price of 25.77 yuan per share [3] Group 2 - Fosun Pharma's subsidiary has had a drug registration application accepted for a new drug targeting ALK-positive non-small cell lung cancer [4] - Leike Film reported a net profit of -86 million yuan for the first three quarters of 2025, indicating a potential annual loss [5] - Crown Stone Technology's application for a specific issuance of A-shares has been accepted by the Shanghai Stock Exchange [6] Group 3 - Dongxin Technology has completed the business registration change for its subsidiary, Lishuan Technology, and has invested 211 million yuan in it [7] - Tianci Materials has increased its commodity futures hedging business limit from 150 million to 300 million yuan [8] - Gaode Infrared's actual controller has reduced his shareholding by 0.54%, bringing his stake down to 62.95% [9] Group 4 - Tianyong Intelligent expects a net profit of 10 million to 15 million yuan for 2025, marking a turnaround from losses [10][11] - China Merchants Energy anticipates a net profit of 6 billion to 6.6 billion yuan for 2025, an increase of 17% to 29% year-on-year [18] - Guangdong Electric Power A's Huizhou Power Plant's Unit 5 has been put into commercial operation, with an investment of 8.05 billion yuan [19] Group 5 - Jianghuai Automobile reported a 42.24% year-on-year increase in sales volume for December 2025 [25] - China Pharmaceutical's subsidiary has received a drug registration certificate for a new medication [26] - TianNeng Co. plans to use up to 12 billion yuan of its own funds for entrusted wealth management [27] Group 6 - Luoyang Huizhong reported a 10.55% month-on-month decrease in sales revenue from live pigs for December 2025 [28] - Baolidi expects a net profit of 145 million to 152 million yuan for 2025, a year-on-year increase of 27.17% to 33.30% [30] - Changchun High-tech's subsidiary has had a melatonin granule registration application accepted [31] Group 7 - Zhongmin Energy reported a 4.46% year-on-year decrease in cumulative on-grid electricity for 2025 [32] - Huaxin Electronics reported a 7.79% year-on-year decrease in consolidated operating revenue for December 2025 [35] - Xiamen Airport reported a 2.79% year-on-year increase in passenger throughput for December 2025 [36] Group 8 - Baiyun Airport reported a 12.27% year-on-year increase in passenger throughput for December 2025 [37] - Pulaike has received a new veterinary drug registration certificate for a chewable tablet [38] - Yunnan Energy Holdings' subsidiary has reduced its stake to 84% after a capital increase [39] Group 9 - Gansu Energy Chemical's new thermal power project has successfully completed trial operation [41] - Zhenghong Technology reported a significant decrease in sales revenue from live pigs for December 2025 [42] - Huasheng Lithium Battery is planning to issue H-shares for listing on the Hong Kong Stock Exchange [43] Group 10 - Jincheng Mining has signed a mining production contract with an estimated total price of approximately 510 million yuan [44] - Microchip Biotech has received approval for clinical trials of a new drug for pancreatic cancer [45] - Yahon Pharmaceutical has completed the first patient enrollment for a Phase I clinical trial of its drug [46]